A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
Status:
Recruiting
Trial end date:
2023-12-28
Target enrollment:
Participant gender:
Summary
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored
trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these
trials until lack of patient benefit as assessed by investigator, or commercial availability
and reimbursement.